The US Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.

Using an innovative and recently validated animal model of IBS, the researchers showed that opioid delta-receptor agonists can ameliorate stress-induced IBS symptoms by acting on the insular cortex of ...

Vistagen , a clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced ...

Vistagen (VTGN) announced that the U.S. Patent and Trademark Office or USPTO, granted a patent to the company for its oral non-opioid product ...

Irritable bowel syndrome (IBS) is a common digestive disorder that affects the intestine, causing symptoms such as abdominal pain, bloating, gas, and ...

Federal officials have approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The U.S.

In Düsseldorf, Algiax Pharmaceuticals is working on a novel analgesic which could provide an effective alternative to opioids, according to new mid-stage data. The firm has just released Phase IIa ...

For those in need, those locations are all in on the fight against drug overdoses. You read that correctly.

The lack of awareness about rare diseases like prurigo nodularis and available treatment options is anticipated to impede market growth.